Christopher Aakre, Ph.D.

Chris joined the Frazier Life Sciences team in 2025, where he focuses on Company Creation.

Prior to joining Frazier Life Sciences, Chris was most recently a Vice President at a Frazier portfolio company, HilleVax, where he played a number of operational, business development, and program management roles. He joined HilleVax as one of its first employees in 2021. Prior to HilleVax, Chris was a Principal at Boston Consulting Group, where he led health care engagements across multiple functions (R&D, BD, Commercial) and therapeutic areas (oncology, vaccines, cell and gene therapy).

Chris received a Ph.D. in Microbiology from the Massachusetts Institute of Technology and a B.S. in Biological Sciences from Stanford University.